Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I study of FF-10501-01 in patients with Myelodysplastic Syndrome and continuous administration study

Next Previous
Trial Profile

Phase I study of FF-10501-01 in patients with Myelodysplastic Syndrome and continuous administration study

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FF 10501 (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Toyama Chemical

    • Most Recent Events

    • 28 Apr 2017 Status changed from recruiting to completed.
    • 24 Dec 2015 According to a Strategia Therapeutics media release, a total of 5 dose cohorts (50-400 mg/m2 orally twice daily) have been enrolled. Additional Phase 1 dose cohorts of 500, 600 and 800 mg/m2 BID will be assessed. The Phase 2 portion of the study will open when a recommended Phase 2 dose is determined
    • 24 Dec 2015 Interim results published at the 57th American Society of Hematology Meeting, according to a Strategia Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top